tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 Target
RatingsOpthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 Target
1d ago
OPT
Opthea announces Phase 2b Wet AMD publication
PremiumThe Fly
Opthea announces Phase 2b Wet AMD publication
1d ago
OPT
Opthea Limited Reports Increased Loss Amid Clinical Progress
PremiumCompany Announcements
Opthea Limited Reports Increased Loss Amid Clinical Progress
1d ago
Opthea’s Sozinibercept Shows Promising Results in Wet AMD Treatment
PremiumCompany Announcements
Opthea’s Sozinibercept Shows Promising Results in Wet AMD Treatment
2d ago
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
PremiumThe Fly
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
4d ago
OPT
Opthea announces anticipated milestones
PremiumThe FlyOpthea announces anticipated milestones
4d ago
OPT
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
Premium
Ratings
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
4d ago
OPT
Opthea Limited Reports Strong Financial Position and Progress in Wet AMD Treatment Trials
Premium
Company Announcements
Opthea Limited Reports Strong Financial Position and Progress in Wet AMD Treatment Trials
5d ago
Opthea Limited Releases Half-Year Financial Report for 2024
PremiumCompany Announcements
Opthea Limited Releases Half-Year Financial Report for 2024
5d ago
Opthea completes drug product PPQ campaign
PremiumThe Fly
Opthea completes drug product PPQ campaign
6d ago
OPT
Opthea Advances Sozinibercept with Successful PPQ Campaign Completion
PremiumCompany Announcements
Opthea Advances Sozinibercept with Successful PPQ Campaign Completion
7d ago
Opthea Limited Announces New Securities Quotation on ASX
PremiumCompany Announcements
Opthea Limited Announces New Securities Quotation on ASX
11d ago
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
PremiumRatingsOptimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
14d ago
OPT
Opthea completes COAST final week 52 patient visit
Premium
The Fly
Opthea completes COAST final week 52 patient visit
14d ago
OPT
Opthea Limited Announces New Securities Quotation on ASX
Premium
Company Announcements
Opthea Limited Announces New Securities Quotation on ASX
15d ago
Opthea Limited Announces Cessation of 3 Million Securities
PremiumCompany Announcements
Opthea Limited Announces Cessation of 3 Million Securities
21d ago
Opthea Limited Announces Quotation of New Securities
PremiumCompany Announcements
Opthea Limited Announces Quotation of New Securities
21d ago
Opthea to Present at Oppenheimer Healthcare Conference
PremiumCompany Announcements
Opthea to Present at Oppenheimer Healthcare Conference
26d ago
Opthea’s Sozinibercept Data to be Highlighted at Macula Society Annual Meeting
PremiumCompany Announcements
Opthea’s Sozinibercept Data to be Highlighted at Macula Society Annual Meeting
27d ago
Opthea Limited Announces Changes in Substantial Holder Interests
PremiumCompany AnnouncementsOpthea Limited Announces Changes in Substantial Holder Interests
28d ago
Opthea Advances Sozinibercept in Phase 3 Trials for Vision Improvement
Premium
Company Announcements
Opthea Advances Sozinibercept in Phase 3 Trials for Vision Improvement
1M ago
Opthea Limited Announces New Securities Quotation
Premium
Company Announcements
Opthea Limited Announces New Securities Quotation
1M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >